Skip to main content
SpringerLink
Log in

18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Malignant Pleural Mesothelioma: What Is the Role in Mesothelioma Detection and Treatment Response Assessment?

  • Chapter
  • First Online:
Malignant Pleural Mesothelioma

  • 473 Accesses

Abstract

Integrated positron emission tomography/computed tomography (PET/CT) with 2-[18F]fluoro-2-deoxyd-glucose (18F-FDG) has emerged as a powerful tool for combined metabolic and anatomic evaluations in clinical oncologic imaging. 18F-FDG PET/CT is also a useful tool to manage patients with malignant pleural mesothelioma, including diagnosis, initial staging, and treatment response assessment. However, a further improvement about PET is desirable.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol. 2009;27:2081–90. https://doi.org/10.1200/JCO.2008.19.8523.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncologyâ„¢. Malignant pleural methothelioma updates in Version 2.2018. https://www2.tri-kobe.org/nccn/guideline/lung/english/mpm.pdf.

  3. Truong MT, Viswanathan C, Godoy MB, Carter BW, Marom EM. Malignant pleural mesothelioma: role of CT, MRI, and PET/CT in staging evaluation and treatment considerations. Semin Roentgenol. 2013;48:323–34. https://doi.org/10.1053/j.ro.2013.03.017.

    Article  PubMed  Google Scholar 

  4. Pass HI, Kranda K, Temeck BK, Feuerstein I, Steinberg SM. Surgically debulked malignant pleural mesothelioma: results and prognostic factors. Ann Surg Oncol. 1997;4:215–22. https://doi.org/10.1007/bf02306613.

    Article  CAS  PubMed  Google Scholar 

  5. Boutin C, Rey F, Gouvernet J, Viallat JR, Astoul P, Ledoray V. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: prognosis and staging. Cancer. 1993;72:394–404. https://doi.org/10.1002/1097-0142(19930715)72:2<394::aid-cncr2820720214>3.0.co;2-5.

    Article  CAS  PubMed  Google Scholar 

  6. Metintas M, Ozdemir N, Isiksoy S, Kaya T, Ekici M, Erginel S, et al. CT-guided pleural needle biopsy in the diagnosis of malignant mesothelioma. J Comput Assist Tomogr. 1995;19:370–4. https://doi.org/10.1097/00004728-199505000-00006.

    Article  CAS  PubMed  Google Scholar 

  7. Bury T, Paulus P, Dowlati A, Corhay JL, Rigo P, Radermecker MF. Evaluation of pleural diseases with FDG-PET imaging: preliminary report. Thorax. 1997;52:187–9. https://doi.org/10.1136/thx.52.2.187.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Benard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest. 1998;114:713–22. https://doi.org/10.1378/chest.114.3.713.

    Article  CAS  PubMed  Google Scholar 

  9. Carretta A, Landoni C, Melloni G, Ceresoli GL, Compierchio A, Fazio F, et al. 18-FDG positron emission tomography in the evaluation of malignant pleural diseases: a pilot study. Eur J Cardiothorac Surg. 2000;17:377–83. https://doi.org/10.1016/s1010-7940(00)00377-8.

    Article  CAS  PubMed  Google Scholar 

  10. Gerbaudo VH, Sugarbaker DJ, Britz-Cunningham S, Di Carli MF, Mauceri C, Treves ST. Assessment of malignant pleural mesothelioma with 18F-FDG dual-head gamma-camera coincidence imaging: comparison with histopathology. J Nucl Med. 2002;43:1144–9.

    PubMed  Google Scholar 

  11. Kramer H, Pieterman RM, Slebos DJ, Timens W, Vaalburg W, Koeter GH, et al. PET for the evaluation of pleural thickening observed on CT. J Nucl Med. 2004;45:995–8.

    PubMed  Google Scholar 

  12. Duysinx B, Nguyen D, Louis R, Cataldo D, Belhocine T, Bartsch P, et al. Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging. Chest. 2004;125:489–93. https://doi.org/10.1378/chest.125.2.489.

    Article  PubMed  Google Scholar 

  13. Yildirim H, Metintas M, Entok E, Ak G, Ak I, Dundar E, et al. Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos related benign pleural disease: an observational pilot study. J Thorac Oncol. 2009;4:1480–4. https://doi.org/10.1097/JTO.0b013e3181c0a7ff.

    Article  PubMed  Google Scholar 

  14. Orki A, Akin O, Tasci AE, Ciftci H, Urek S, Falay O, et al. The role of positron emission tomography/computed tomography in the diagnosis of pleural diseases. Thorac Cardiovasc Surg. 2009;57:217–21. https://doi.org/10.1055/s-2008-1039314.

    Article  CAS  PubMed  Google Scholar 

  15. Terada T, Tabata C, Tabata R, Okuwa H, Kanemura S, Shibata E, et al. Clinical utility of 18-fluorodeoxyglucose positron emission tomography/computed tomography in malignant pleural mesothelioma. Exp Ther Med. 2012;4:197–200. https://doi.org/10.3892/etm.2012.572.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Elboga U, Yılmaz M, Uyar M, Zeki Çelen Y, Bakır K, Dikensoy O. The role of FDG PET-CT in differential diagnosis of pleural pathologies. Rev Esp Med Nucl Imagen Mol. 2012;31:187–91. https://doi.org/10.1016/j.remn.2011.06.002.

    Article  CAS  PubMed  Google Scholar 

  17. Abe Y, Tamura K, Sakata I, Ishida J, Ozeki Y, Tamura A, et al. Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma. Oncol Rep. 2012;27:333–8. https://doi.org/10.3892/or.2011.1520.

    Article  CAS  PubMed  Google Scholar 

  18. Roca E, Laroumagne S, Vandemoortele T, Berdah S, Dutau H, Maldonado F, et al. 18F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography fused imaging in malignant mesothelioma patients: looking from outside is not enough. Lung Cancer. 2013;79:187–90. https://doi.org/10.1016/j.lungcan.2012.10.017.

    Article  PubMed  Google Scholar 

  19. Nguyen NC, Tran I, Hueser CN, Oliver D, Farghaly HR, Osman MM. F-18 FDG PET/CT characterization of talc pleurodes is induced pleural changes over time: a retrospective study. Clin Nucl Med. 2009;34:886–90. https://doi.org/10.1097/RLU.0b013e3181bece11.

    Article  PubMed  Google Scholar 

  20. Kitajima K, Doi H, Kuribayashi K. Present and future roles of FDG-PET/CT imaging in the management of malignant pleural mesothelioma. Jpn J Radiol. 2016;34:537–47. https://doi.org/10.1007/s11604-016-0555-1.

    Article  CAS  PubMed  Google Scholar 

  21. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma: from the international mesothelioma interest group. Chest. 1995;108:1122–8. https://doi.org/10.1378/chest.108.4.1122.

    Article  CAS  PubMed  Google Scholar 

  22. Erasmus JJ, Truong MT, Smythe WR, Munden RF, Marom EM, Rice DC, et al. Integrated computed tomography–positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: staging implications. J Thorac Cardiovasc Surg. 2005;129:1364–70. https://doi.org/10.1016/j.jtcvs.2004.10.034.

    Article  PubMed  Google Scholar 

  23. Wilcox BE, Subramaniam RM, Peller PJ, Aughenbaugh GL, Nichols Iii FC, Aubry MC, et al. Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma. Clin Lung Cancer. 2009;10:244–8. https://doi.org/10.3816/CLC.2009.n.033.

    Article  PubMed  Google Scholar 

  24. Ambrosini V, Rubello D, Nanni C, Farsad M, Castellucci P, Franchi R, et al. Additional value of hybrid PET/CT fusion imaging vs. conventional CT scan alone in the staging and management of patients with malignant pleural mesothelioma. Nucl Med Rev Cent East Eur. 2005;8:111–5.

    PubMed  Google Scholar 

  25. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004;15:257–60. https://doi.org/10.1093/annonc/mdh059.

    Article  CAS  PubMed  Google Scholar 

  26. Ceresoli GL, Chiti A, Zucali PA, Rodari M, Lutman RF, Salamina S, et al. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F] fluorodeoxyglucose. J Clin Oncol. 2006;24:4587–93. https://doi.org/10.1200/JCO.2006.06.8999.

    Article  PubMed  Google Scholar 

  27. Lopci E, Zucali PA, Ceresoli GL, Perrino M, Giordano L, Gianoncelli L, et al. Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma. Eur J Nucl Med Mol Imaging. 2015;42:667–75. https://doi.org/10.1007/s00259-014-2960-y.

    Article  PubMed  Google Scholar 

  28. Tsutani Y, Takuwa T, Miyata Y, Fukuoka K, Hasegawa S, Nakano T, et al. Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma. Ann Oncol. 2013;24:1005–10. https://doi.org/10.1093/annonc/mds537.

    Article  CAS  PubMed  Google Scholar 

  29. Kitajima K, Doi H, Kuribayashi K, Hashimoto M, Tsuchitani T, Tanooka M, et al. Prognostic value of pretreatment volume-based quantitative 18F-FDG PET/CT parameters in patients with malignant pleural mesothelioma. Eur J Radiol. 2017;86:176–83. https://doi.org/10.1016/j.ejrad.2016.11.019.

    Article  PubMed  Google Scholar 

  30. Francis RJ, Byrne MJ, van der Schaaf AA, Boucek JA, Nowak AK, Phillips M, et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume based analysis of serial 18F-FDG PET scans. J Nucl Med. 2007;48:1449–58. https://doi.org/10.2967/jnumed.107.042333.

    Article  PubMed  Google Scholar 

  31. Veit-Haibach P, Schaefer NG, Steinert HC, Soyka JD, Seifert B, Stahel RA. Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma. Lung Cancer. 2010;67:311–7. https://doi.org/10.1016/j.lungcan.2009.04.015.

    Article  PubMed  Google Scholar 

  32. Schaefer NG, Veit-Haibach P, Soyka JD, Steinert HC, Stahel RA. Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT. Eur J Radiol. 2012;81:e19–25. https://doi.org/10.1016/j.ejrad.2010.11.006.

    Article  PubMed  Google Scholar 

  33. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773–82. https://doi.org/10.1016/s0959-8049(99)00229-4.

    Article  CAS  PubMed  Google Scholar 

  34. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S–50S. https://doi.org/10.2967/jnumed.108.057307.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Kanemura S, Kuribayashi K, Funaguchi N, Shibata E, Mikami K, Doi H, et al. Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma. Eur J Radiol. 2017;86:92–8. https://doi.org/10.1016/j.ejrad.2016.11.009.

    Article  PubMed  Google Scholar 

  36. Kitajima K, Nakamichi T, Hasegawa S, Kuribayashi K, Yamakado K. Fluorodeoxyglucose versus choline positron emission tomography/computed tomography response evaluation in two malignant pleural mesothelioma patients treated with talc pleurodesis and neoadjuvant chemotherapy. Cureus. 2018;10(11):e3654. https://doi.org/10.7759/cureus.3654.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nuclear Medicine and PET Center, Department of Radiology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan

    Kazuhiro Kitajima

  2. Department of Radiation Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan

    Hiroshi Doi

  3. Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan

    Kozo Kuribayashi

Authors
  1. Kazuhiro Kitajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroshi Doi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kozo Kuribayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Center Respiratory Medicine, Otemae Hospital, Osaka, Japan

    Takashi Nakano

  2. Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan

    Takashi Kijima

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kitajima, K., Doi, H., Kuribayashi, K. (2021). 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Malignant Pleural Mesothelioma: What Is the Role in Mesothelioma Detection and Treatment Response Assessment?. In: Nakano, T., Kijima, T. (eds) Malignant Pleural Mesothelioma. Respiratory Disease Series: Diagnostic Tools and Disease Managements. Springer, Singapore. https://doi.org/10.1007/978-981-15-9158-7_18

Download citation

  • DOI: https://doi.org/10.1007/978-981-15-9158-7_18

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-15-9157-0

  • Online ISBN: 978-981-15-9158-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation